Hives, also known as urticaria, are an inflammatory skin condition characterized by transient itchy wheals that can vary in size and location. Episodes may be acute or chronic and can be triggered by allergic, infectious, physical, or idiopathic factors. Severe cases can be associated with angioedema.
Novartis announced positive European regulatory opinion for remibrutinib in chronic spontaneous urticaria and reported the drug met its primary endpoint in a Phase 3 trial for chronic inducible urticaria.
Novartis announced positive Phase III RemIND trial results for oral remibrutinib in chronic inducible urticaria, marking the first therapy to meet a Phase III primary endpoint in the condition. The company has submitted a supplemental New Drug Application to the FDA.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05936567 |
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria |
COMPLETED | PHASE2 |
| NCT03968562 |
Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline |
UNKNOWN | PHASE2 |
| NCT01371877 |
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment |
COMPLETED | NA |
